Enhanced efficacy of the acyclic nucleoside 9-(1,3-dihydroxy-2-propoxymethyl)guanine in combination with alpha-interferon against herpes simplex virus type 2 in mice.
The acyclic nucleoside DHPG [9-(1,3-dihydroxy-2-propoxymethyl)guanine] and recombinant human alpha-interferon of clones A/D potentiate each other's antiviral activity against a systemic infection with herpes simplex virus type 2. The effective dose at which 50% of the mice survived was lowered approximately 10-fold for DHPG when it was given in combination with a marginally effective dose of alpha-interferon and greater than 10-fold for alpha-interferon when it was given in combination with a nontherapeutic dose of DHPG.
D000212:Acyclovir / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000818:Animals; D000998:Antiviral Agents / Q000627:therapeutic use*; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D005260:Female; D015774:Ganciclovir; D006561:Herpes Simplex / Q000188:drug therapy*; D007370:Interferon Type I / Q000627:therapeutic use*; D051379:Mice
D000998:Antiviral Agents; D007370:Interferon Type I; D015774:Ganciclovir; D000212:Acyclovir